Benzinga··Vandana SinghEli Lilly's Oral Weight Loss Drug Clears Cardiovascular Safety Hurdle
Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.
LLYFDA approvalweight-loss drug